Table 1 Main clinical features and distribution of the components of the metabolic syndrome in the 753 haemodialysis patients with or without metabolic syndrome
MetS+ | MetS- | p | ||
|---|---|---|---|---|
Prevalence. n (%) | 516 (68.5) | 237 (31.5) | ||
Gender, n (%) | ||||
men | 282 (54.7) | 154 (65.0) | < 0.01 | |
women | 234 (45.3) | 83 (35) | ||
Age, years | 66.6 ± 0.5 | 63.3 ± 1.1 | < 0.01 | |
Body height, cm | 165.2 ± 0.4 | 165.7 ± 0.6 | 0.50 | |
Weight, kg | 79.2 ± 0.8 | 64.4 ± 0.9 | < 0.01 | |
Dialysis vintage, years | 5.0 ± 0.2 | 6.4 ± 0.5 | < 0.01 | |
Serum albumin, g/L | 37.7 ± 0.2 | 37.9 ± 0.3 | 0.60 | |
BMI, kg/m2 | 29.0 ± 0.3 | 23.4 ± 0.3 | < 0.01 | |
BMI > 30, n (%) | 195 (38) | 12 (8) | < 0.01 | |
BMI 25–30, n (%) | 184 (36) | 50 (21) | < 0.01 | |
BMI < 20, n (%) | 13 (3) | 51 (22) | < 0.01 | |
Diabetes, n (%) | 299 (58) | 44 (19) | < 0.01 | |
HbA1c, % | 6.7 ± 0.2 | 5.8 ± 0.1 | 0.01 | |
Statin use, n (%) | 329 (64) | 121 (51) | < 0.01 | |
Smoking, n (%) | 228 (54) | 103 (53) | 0.80 | |
WC, cm | 107.4 ± 0.6 | 90.2 ± 0.8 | < 0.01 | |
Fasting glucose, g/L | 1.3 ± 0.03 | 1.0 ± 0.03 | < 0.01 | |
HDL, mmol/L | 1.0 ± 0.02 | 1.4 ± 0.03 | < 0.01 | |
with statin, mmol/L | 1.0 ± 0.02 | 1.4 ± 0.03 | < 0.01 | |
without statin, mmol/L | 1.1 ± 0.02 | 1.4 ± 0.03 | < 0.01 | |
TG, mmol/L | 2.4 ± 0.06 | 1.3 ± 0.03 | < 0.01 | |
with statin, mmol/L | 2.5 ± 0.06 | 1.3 ± 0.03 | < 0.01 | |
without statin, mmol/L | 2.1 ± 0.06 | 1.3 ± 0.03 | < 0.01 | |
LDL, mmol/L | 3.1 ± 0.1 | 3.5 ± 0.2 | 0.03 | |
with statin, mmol/L | 2.9 ± 0.1 | 2.9 ± 0.1 | 0.63 | |
without statin, mmol/L | 3.5 ± 0.1 | 4.1 ± 0.2 | 0.06 | |
MsWC, N (%) | 414 (80) | 42 (18) | < 0.01 | |
men | 197 (70) | 16 (10) | < 0.01 | |
women | 217 (93) | 26 (31) | < 0.01 | |
MsHBP, n (%) | 483 (74) | 174 (26) | < 0.01 | |
MsHDL, n (%) | 333 (67) | 24 (10) | < 0.01 | |
men | 187 (66) | 13 (8) | < 0.01 | |
women | 146 (62) | 11 (13) | < 0.01 | |
MsTG, n (%) | 330 (69) | 36 (16) | < 0.01 | |
MsGlc, n (%) | 423 (85) | 93 (43) | < 0.01 | |